Evidence map›Paper›PMID 34547468›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2022

PD-L1

Qing Li, Zhi-Wei Zhou, Jia Lu, Hao Luo, Shu-Nan Wang, Yu Peng, Meng-Sheng Deng, Guan-Bin Song, Jian-Min Wang, Xi Wei and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Qing LiCancer Center, Daping Hospital, Army Medical University, Chongqing 400042, China; School of Medicine, Chongqing University, Chongqing 400030, China.
Zhi-Wei ZhouDepartment of Radiation Oncology and Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Jia LuDepartment of Radiation Oncology and Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Hao LuoCancer Center, Daping Hospital, Army Medical University, Chongqing 400042, China; Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400030, China.
Shu-Nan WangDepartment of Radiology, Daping Hospital, Army Medical University, Chongqing 400042, China.
Yu PengShanghai Key Laboratory of Regulatory Biology, The Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China.
Meng-Sheng DengState Key Laboratory of Trauma, Burn and Combined Injury, Daping Hospital, Army Medical University, Chongqing 400042, China.
Guan-Bin SongKey Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400030, China.
Jian-Min WangState Key Laboratory of Trauma, Burn and Combined Injury, Daping Hospital, Army Medical University, Chongqing 400042, China.
Xi WeiDepartment of Diagnostic Ultrasound, Tianjin Medical University Cancer Institute and Hospital, Tianjin 330006, China.
Dong WangCancer Center, Daping Hospital, Army Medical University, Chongqing 400042, China. Electronic address: dongwang64@hotmail.com.
Kenneth D WestoverDepartment of Radiation Oncology and Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: Kenneth.westover@utsouthwestern.edu.
Cheng-Xiong XuCancer Center, Daping Hospital, Army Medical University, Chongqing 400042, China; School of Medicine, Chongqing University, Chongqing 400030, China. Electronic address: xuchengxiong@cqu.edu.cn.
Army Medical University · CNThe University of Texas Southwestern Medical Center · USChongqing University · CNEast China Normal University · CNSouthwestern Medical Center · USTianjin Medical University Cancer Institute and Hospital · CN

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MELANIE H. COBB · 2010 to 2026
$53.7M
NCI NIH HHS P30 CA142543
6 · The paper itself

Abstract

Cancer cells evade immune detection via programmed cell death 1/programmed cell death-ligand 1 (PD-1/PD-L1) interactions that inactivate T cells. PD-1/PD-L1 blockade has become an important therapy in the anti-cancer armamentarium. However, some patients do not benefit from PD-1/PD-L1 blockade despite expressing PD-L1. Here, we screened 101 gastric cancer (GC) patients at diagnosis and 141 healthy control subjects and reported one such subpopulation of GC patients with rs17718883 polymorphism in PD-L1, resulting in a nonsense P146R mutation. We detected rs17718883 in 44% of healthy control subjects, and rs17718883 was associated with a low susceptibility to GC and better prognosis in GC patients. Structural analysis suggests that the mutation weakens the PD-1:PD-L1 interaction. This was supported by co-culture experiments of T cells, with GC cells showing that the P146R substitution results in interferon (IFN)-γ secretion by T cells and enables T cells to suppress GC cell growth. Similar results with animal gastric tumor models were obtained in vivo. PD-1 monoclonal antibody treatment did not enhance the inhibitory effect of T cells on GC cells expressing PD-L1

Indexed as

Stomach NeoplasmsAnimalsB7-H1 AntigenHumansImmunotherapyPrognosisT-LymphocytesB7-H1 Antigengastric cancerimmunotherapyPD-1/PD-L1polymorphism

Identifiers

PMID34547468
PMCPMC8821936
OpenAlexW3200377577

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.